HomeAgenda

SANSHO Co., Ltd.

Company (SME/startup) / 中小企業・スタートアップ

www.c-pa.jp/encompanyprofile.htmlTokyo, Japan
39 profile visits

About

SANSHO Co., Ltd. is a biotech venture company operating in three business areas: pharmaceuticals, cosmetics, and food, leveraging its core technology of cyclic phosphatidic acid (cPA), a result of research at Ochanomizu University.

In its core pharmaceutical business, SANSHO is building multiple pipelines by leveraging cPA's unique mechanisms of action, including anti-inflammatory, tissue regenerative, and anti-fibrotic properties. One such pipeline, SSO-001, is a new compound with the potential to promote cartilage regeneration and is currently progressing smoothly in clinical trials overseas.

Other pipelines in the development stage include SSI-002, a drug for idiopathic pulmonary fibrosis, and SSG-003, a drug for glaucoma.

SANSHO also sells cPA as a cosmetic and food ingredient. The products developed using technology cultivated through pharmaceutical development have received a certain level of recognition in the market, and the company is working to further expand its business.

Social media

Business Domain / 分野

Pharmaceuticals / 医薬品Healthcare / ヘルスケア

Business Type / 業種

R&D / 研究開発

Disease Area / 疾患領域

Oncology / がんNeurology & Psychiatry / 中枢神経、精神疾患Immunology / 免疫・炎症Metabolic diseases / 代謝Musculoskeletal System / 筋骨格系Dermatology and sensory system / 皮膚・感覚器Rare diseases / 希少疾患Others / その他

Modalities / モダリティ

Small-molecule drug / 低分子医薬Others /その他

Additional questions

Researched company/organisation type / マッチングご希望企業・機関のタイプ

Major pharma etc. (Out-licensing purpose) / 大手ファーマ等(アウトライセンスを目的)

Researched disease area / マッチングご希望の疾患領域

Oncology / がんNeurology & Psychiatryy / 中枢神経、精神疾患Immunology / 免疫・炎症Musculoskeletal System / 筋骨格系Dermatology and sensory system / 皮膚・感覚器Rare diseases / 希少疾患Others /その他

Researched Modality / マッチングご希望のモダリティ

Small-molecule drug/低分子医薬

Researched Technologies / マッチングご希望の技術

Others /その他

Marketplace (5)

  • Project cooperation

    SSO-001 for Osteoarthritis (OA)

    SSO-001 may act as a disease-modifying drug and relieves OA associated symptoms, completed Phase IIa clinical study.

    • Research
    • Execution
    • Technical
    • Financing
    • Sales/Distribution
  • Project cooperation

    SSG-003 for Glaucoma

    SSG-003 offers a new approach to glaucoma treatment.

    • Research
    • Execution
    • Technical
    • Financing
    • Sales/Distribution